维奈克拉-利妥昔单抗联合或不联合苯达莫司汀对比苯达莫司汀-利妥昔单抗治疗复发/难治性滤泡性淋巴瘤
CONTRALTO 开放标签2期研究评估维奈克拉联合利妥昔单抗(VEN+R)、维奈克拉联合苯达莫司汀和利妥昔单抗(VEN+BR)对比苯达莫司汀联合利妥昔单抗(BR)治疗复发/难治性滤泡性淋巴瘤。共分析163例患者,完全代谢/完全缓解率在A组(VEN+R)为17%、B组(VEN+BR)为75%、C组(BR)为69%;B组3/4级不良事件率93.9%,高于C组的60.0%和A组的51.9%。VEN+BR较BR毒性增加且BR剂量强度降低,但疗效相似;VEN+R数据需进一步研究。
要点
- VEN+BR组完全代谢/完全缓解率为75%,BR组为69%,VEN+R组为17%。
- VEN+BR组仅61%患者接受≥90%计划苯达莫司汀剂量,BR组为96%。
- VEN+BR组3/4级不良事件率为93.9%,BR组为60.0%,VEN+R组为51.9%。
核心结论
- VEN+BR较BR毒性增加且BR剂量强度降低,但疗效相似。
- 优化剂量和方案以维持BR剂量强度可能改善VEN+BR的疗效和耐受性,VEN+R数据需进一步研究。
研究设计与样本
- 开放标签2期研究(CONTRALTO),纳入复发/难治性滤泡性淋巴瘤患者。
- 无化疗组(A组)接受VEN 800 mg/d联合R 375 mg/m2(第1周期第1、8、15、22天及第4、6、8、10、12周期第1天)。
- 含化疗队列经VEN 600 mg安全性导入后随机分配至VEN+BR组(B组;VEN 800 mg/d用1年+6周期BR[苯达莫司汀90 mg/m2第1、2天,利妥昔单抗375 mg/m2第1天])或6周期BR组(C组)。
- 共分析163例患者(安全性导入9例,A组52例、B组51例、C组51例)。
- 研究注册号NCT02187861。
主要发现
- 完全代谢/完全缓解率:A组17%、B组75%、C组69%。
- B组仅61%患者接受≥90%计划苯达莫司汀剂量,C组为96%。
- B组较C组因血液学毒性更频繁导致更多减量/治疗中断。
- 3/4级不良事件率:A组51.9%、B组93.9%、C组60.0%。
临床怎么用
- 作者认为优化剂量和方案以维持BR剂量强度可能改善VEN+BR的疗效和耐受性。
- 作者认为VEN+R数据需进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This open-label phase 2 study (CONTRALTO) assessed the safety and efficacy of BCL-2 inhibitor venetoclax (VEN) plus rituximab (R), and VEN plus bendamustine (B) and R, vs B + R (BR) alone in relapsed/refractory (R/R) follicular lymphoma. Patients in the chemotherapy-free arm (arm A: VEN + R) received VEN 800 mg/d plus R 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 4, 6, 8, 10, and 12. After a safety run-in with VEN 600 mg, patients in the chemotherapy-containing cohort were randomized to either VEN + BR (arm B; VEN 800 mg/d for 1 year + 6 cycles of BR [B 90 mg/m2 on days 1 and 2 and R 375 mg/m2 on day 1]) or 6 cycles of BR (arm C). Overall, 163 patients were analyzed (9 in the safety run-in and 52, 51, and 51 in arms A, B, and C, respectively). Complete metabolic/complete response rates were 17% (arm A), 75% (arm B), and 69% (arm C). Of patients in arm B, only 61% received ≥90% of the planned B dose vs 96% of patients in arm C. More frequent hematologic toxicity resulted in more reduced dosing/treatment discontinuation in arm B vs arm C. Rates of grade 3/4 adverse events were 51.9%, 93.9%, and 60.0% in arms A, B, and C, respectively. VEN + BR led to increased toxicity and lower dose intensity of BR than in arm C, but efficacy was similar. Optimizing dose and schedule to maintain BR dose intensity may improve efficacy and tolerability of VEN + BR, while VEN + R data warrant further study. This study was registered at www.clinicaltrials.gov as #NCT02187861.
引用
- Zinzani PL, Flinn IW, Yuen SLS, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020. PMID: 32785666. doi:10.1182/blood.2020005588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。